Marie Varloteaux

Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

Alexandra Calmy, Tamara Tovar-Sanchez, Charles Kouanfack et al. · The Lancet HIV · 2020 · 164 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Viral load suppression in HIV-infected adolescents in cameroon: towards achieving the UNAIDS 95% viral suppression target

Armando B D Djiyou, Calixte Ida Penda, Yoann Madec et al. · BMC Pediatrics · 2023 · 28 citations · Full text

Public Health, Infectious Diseases, Pediatrics +17

Rapid Increase of Community SARS-CoV-2 Seroprevalence during Second Wave of COVID-19, Yaoundé, Cameroon

Francis Atéba Ndongo, Emilande Guichet, Eric Mimbe et al. · Emerging infectious diseases · 2022 · 24 citations · Full text

Veterinary Medicine, Community Health, Infectious Diseases +7

Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)

Marwân‐al‐Qays Bousmah, Marie Libérée Nishimwe, Tamara Tovar-Sanchez et al. · PharmacoEconomics · 2020 · 16 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Acceptability of Outpatient Ready-To-Use Food-Based Protocols in HIV-Infected Senegalese Children and Adolescents Within the MAGGSEN Cohort Study

Cécile Cames, Marie Varloteaux, Ndeye Ngoné Have et al. · Food and Nutrition Bulletin · 2016 · 11 citations

Agriculture, Child Health, Nutrition +17